TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701 ...

News headlines TG Therapeutics has shown a 160% gain over the past three years despite recent challenges. Positive clinical updates and strong Q3 earnings have renewed investor interest, yet concerns ...

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United ...